An Exploration of Relative Health Stock in Advanced Cancer Patients

Darrell J. Gaskin, Kevin P. Weinfurt, Liana D. Castel, Venita DePuy, Yun Li, Andrew Balshem, Al Benson, Caroline B. Burnett, Sandra Corbett, John Marshall, Elyse Slater, Daniel P. Sulmasy, David Van Echo, Neal J. Meropol and Kevin A. Schulman
Additional contact information
Darrell J. Gaskin: Johns Hopkins University, Baltimore, Maryland
Kevin P. Weinfurt: Duke University, Durham, North Carolina
Liana D. Castel: Duke University, Durham, North Carolina
Venita DePuy: Duke University, Durham, North Carolina
Yun Li: Duke University, Durham, North Carolina
Andrew Balshem: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Al Benson: Northwestern University, Chicago, Illinois
Caroline B. Burnett: Georgetown University, Washington, DC
Sandra Corbett: Fox Chase Cancer Center, Philadelphia, Pennsylvania
John Marshall: Georgetown University, Washington, DC
Elyse Slater: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Daniel P. Sulmasy: St. Vincent’s Manhattan and New York Medical College, New York, New York
David Van Echo: University of Maryland, Baltimore
Neal J. Meropol: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Kevin A. Schulman: Duke University, Durham, North Carolina

Medical Decision Making, 2004, vol. 24, issue 6, 614-624

Abstract: Objective. The authors sought to empirically test whether relative health stock, a measure of patients’ sense of loss in their health due to illness, influences the treatment decisions of patients facing life-threatening conditions. Specifically, they estimated the effect of relative health stock on advanced cancer patients’ decisions to participate in phase I clinical trials. Method. A multicenter study was conducted to survey 328 advanced cancer patients who were offered the opportunity to participate in phase I trials. The authors asked patients to estimate the probabilities of therapeutic benefits and toxicity, their relative health stock, risk preference, and the importance of quality of life. Results. Controlling for health-related quality of life, an increase in relative health stock by 10 percentage points reduced the odds of choosing to participate in a phase I trial by 16% (odds ratio = 0.84, 95% confidence interval = 0.72, 0.97). Conclusion. Relative health stock affects advanced cancer patients’ treatment decisions.

Keywords: patient preferences; decision making; clinical trials; cancer; phase I trials (search for similar items in EconPapers)
Date: 2004
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X04271041 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:24:y:2004:i:6:p:614-624

DOI: 10.1177/0272989X04271041

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().